Combination therapy for treatment of myeloproliferative neoplasms
US11833155B2 · kind B2 · utility
0Cited by
158References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 2, 2021 |
| Grant date | Dec 5, 2023 |
| Priority date | — |
| Expiry date | Feb 11, 2042 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present application relates to treatment of myeloproliferative neoplasms using the JAK1/JAK2 inhibitor, ruxolitinib, in combination with a BET protein inhibitor, 2,2,4-trimethyl-8-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-6-(methylsulfonyl)-2H-1,4-benzoxazin-3(4H)-one, wherein the combination is unexpectedly synergistic.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.